BC Week In Review | Jun 8, 2018
Clinical News

Keytruda monotherapy benefit extended to low PD-L1 expression, though doubts linger

Detailed data from the Phase III KEYNOTE-042 trial showed that Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) given as monotherapy in the first-line setting could be further extended to treat non-small cell lung cancer...
Items per page:
1 - 1 of 1